Sign In
Buy RAPT
$58.02
+0 (+0%)
At Close: Jun 01, 2026
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of RAPT Therapeutics, Inc. - RAPT
06:06pm, Monday, 11'th Mar 2024
NEW YORK, March 11, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of RAPT Therapeutics, Inc. ("RAPT" or the "Company") (NASDAQ: RAPT). Such investors are advis
Should You Buy RAPT Therapeutics (RAPT) Ahead of Earnings?
09:41am, Thursday, 07'th Mar 2024
RAPT Therapeutics (RAPT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
08:00am, Thursday, 07'th Mar 2024
SOUTH SAN FRANCISCO, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and c
Includes late-breaking poster presentation to highlight phase 2 clinical data for tivumecirnon in head and neck cancer Includes late-breaking poster presentation to highlight phase 2 clinical data for
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of RAPT Therapeutics, Inc. - RAPT
10:15am, Sunday, 03'rd Mar 2024
NEW YORK , March 3, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of RAPT Therapeutics, Inc. ("RAPT" or the "Company") (NASDAQ: RAPT). Such investors are advised
NEW YORK--(BUSINESS WIRE)---- $RAPT #classaction--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of RAPT Therapeutics, Inc. (“RAPT
Rapt Therapeutics Crashes 65% After Unexpected Liver Failure Sidelines Two Tests
12:14pm, Tuesday, 20'th Feb 2024
Biotech stock Rapt plummeted to a record low Tuesday after the Food and Drug Administration put two of its clinical studies on hold.
RAPT Therapeutics' stock plunges as FDA halts two clinical trials
08:36am, Tuesday, 20'th Feb 2024
RAPT Therapeutics Inc. shares RAPT, +1.68% dropped more than 60% premarket on Tuesday after the company said regulators have hit pause on two clinical trials of its experimental inflammation treatment
RAPT Therapeutics Announces Clinical Hold on Studies Evaluating Zelnecirnon
07:30am, Tuesday, 20'th Feb 2024
- RAPT to host a conference call today at 8:30 am ET - SOUTH SAN FRANCISCO, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biophar
SOUTH SAN FRANCISCO, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and co
RAPT Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
08:00am, Wednesday, 31'st Jan 2024
SOUTH SAN FRANCISCO, Calif., Jan. 31, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and co
RAPT Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
08:00am, Tuesday, 02'nd Jan 2024
SOUTH SAN FRANCISCO, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and co
SOUTH SAN FRANCISCO, Calif., Nov. 27, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing a
RAPT Therapeutics Reports Third Quarter 2023 Financial Results
08:00am, Monday, 13'th Nov 2023
SOUTH SAN FRANCISCO, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and co
- Confirmed objective response rate (ORR) of 40% in PD-L1 positive (TPS ≥ 1%) patients with no prior checkpoint inhibitor therapy (CPI)
